Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$178K+36.9%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$0-100%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$6.54M-5.0%
VAN
Vivani MedicalVANI
$1.78M+35.9%
uniQure logo
uniQureQURE
$2.99M-23.5%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2.22M-32.6%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$45.7M-6.6%
Net income-$43.4M-4.8%
EPS (diluted)-$0.39+15.2%

Balance sheet

See full
Cash & equivalents$49.3M-15.1%
Total debt$5.3M-11.9%
Total equity$239.2M+42.5%
Total assets$264.6M+36.0%

Cash flow

See full
Operating cash flow-$31.4M-24.5%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$2.54B+265%
Enterprise value$2.5B+287%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-74.7%-9.5pp
Debt / equity0.0×
Current ratio12.1×+3.4×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 7:04 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336682

FAQ

What is Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Amylyx Pharmaceuticals, Inc. (AMLX) reported operating lease liabilities (current) of $1.01M in Q2 2026.
How has Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) increased by 51.6% year-over-year, from $665K to $1.01M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a -14.9% compound annual growth rate (CAGR), from $2.04M to $1.26M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Amylyx Pharmaceuticals, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude